Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02290431 · OUTCOME

Minimal Response Rate (MRR) Per Investigator

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2019-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
after 24 weeks (8 cycles; cycle = 21 days)

What was measured

MRR is based on modified EBMT criteria per investigator assessment

Analysis population: FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.

Groups in this outcome

LBH589 + Bortezomib + Dexamethasone

Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone31

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
LBH589 + Bortezomib + Dexamethasone9.7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9.7
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
MRR is based on modified EBMT criteria per investigator assessment
groups
  1. description
    Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
    id
    OG000
    title
    LBH589 + Bortezomib + Dexamethasone
param Type
NUMBER
population Description
FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.
reporting Status
POSTED
time Frame
after 24 weeks (8 cycles; cycle = 21 days)
title
Minimal Response Rate (MRR) Per Investigator
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice